Navigation Links
Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
Date:11/28/2012

has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of September 30, 2012, more than 10,000 physicians in over 65 countries had ordered more than 320,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the outcome of future studies; the ability of the company to develop additional tests in the future, the demand for the Company's products, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-look
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Childrens Hospital announces international genomics competition winner
2. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
3. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
4. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
5. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
6. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
7. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
8. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
9. Increase in Genomic Replikin Counts Predicted Recent Avian Flu (H5N1) Outbreak in Cambodia
10. First Plant Genomics Yield Technology Progresses
11. Genomic Vision Extends its Patent Portfolio With the Genomic Morse Code
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... CITY, Calif. , March 4, 2015 /PRNewswire/ ... ), a specialty pharmaceutical company focused on the ... treatment of acute and breakthrough pain, today announced ... 2014 financial results after market close on Monday, ... investment-community conference call at 4:30 p.m. Eastern Time ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015   ... Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für die ... Royal Philips (NYSE: PHG, AEX: PHIA) gab ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... This release is available in German . ... Science (CFEL) have built the world,s smallest magnetic data storage unit. ... information, and squeezes a whole byte (8 bit) into as few ... more than half a billion atoms per byte. The team present ...
... cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), ... NBS ) ("NeoStem" or the "Company"), announced today ... and regulatory services related to the development of ... injectable suspension of microencapsulated insulin-producing, pancreatic islet cells ...
... have imagined that the world would be seriously concerned over ... periodic table, dysprosium was once just another element for chemistry ... sought-after and critically needed materials on the planet. Belonging ... earths-dysprosium and other rare earths are used in almost every ...
Cached Biology Technology:The world's smallest magnetic data storage unit 2The world's smallest magnetic data storage unit 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4Berkeley Lab seeks to help US assert scientific leadership in critical materials 2Berkeley Lab seeks to help US assert scientific leadership in critical materials 3Berkeley Lab seeks to help US assert scientific leadership in critical materials 4Berkeley Lab seeks to help US assert scientific leadership in critical materials 5
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... State University researcher is exploring a new method of ... is more effective and reliable than using eye drops. ... clinical sciences at Iowa State,s College of Veterinary Medicine, ... method of implanting biodegradable medicine into the tissue surrounding ...
... mechanism has been discovered in a microorganism that thrives in ... key processes in human cells, and in a better understanding ... study is published today in the online version the American ... group at the Department of Molecular Evolution at Uppsala University ...
... chemicals, such as methylmercury can cause harm at levels ... evidence in the International Journal of Environment and ... approach to this and similar compounds to protect unborn ... the Department of Environmental Health at Harvard School of ...
Cached Biology News:Iowa State researcher develops new treatment method for canine eye diseases 2Iowa State researcher develops new treatment method for canine eye diseases 3New cell division mechanism discovered 2Methylmercury warning 2
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
... The kit contains all the reagents required ... NADPH-cytochrome c reductase activity in cell and ... reticulum (ER)]. It has been tested on ... liver, kidney, brain, spleen, and heart muscle ...
... pET Host Strain Competent Cell Sets ... vector/host strain combinations The most ... E. coli is to use ... be prepared in the laboratory, greater efficiency, ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
Biology Products: